Total parietal peritonectomy leads to a low incidence of platinum resistance in patients undergoing interval cytoreductive surgery for advanced epithelial serous ovarian cancer- results of a prospective multi-centric study
Preprint
Abstract
Background and Aim: Though interval cytoreductive surgery (CRS) following neoadjuvant chemotherapy (NACT) is considered non-inferior to primary CRS, the incidence of platinum resistance is high. A total parietal peritonectomy (TPP) can address occult microscopic disease more completely and could reduce the rates of early recurrence. The early results of a prospective study evaluating the role of TPP are presented in this manuscript. Methods: This is a prospective, multi-centric interventional study. A TPP was performed in all patients undergoing interval CRS. A fixed surgical protocol was followed. Grade 3-4 morbidity was recorded. Factors affecting grade 3-4 morbidity, early recurrence and progression-free survival (PFS) were evaluated. Results: From July 2018, 70 patients with serous carcinoma were included. The median surgical PCI was 15 [range 5-37]. A CC-0 resection was obtained in 55(78.5%) patients; CC-1 in 10(14.2%). Grade 3-4 complications were seen in 15(21.4%) patients of which the commonest complication was intraperitoneal fluid collection. Occult disease in the peritoneum was seen in 40%. Early recurrence (platinum resistance) was seen in 5(7.1%). The median PFS was 18 months [range 0-21months]. Patients with a lower PCI and with no grade 3-4 complications had a significantly longer PFS. A pathological PCI>15 was the only independent predictor of a shorter PFS (p=0.001). Conclusions: TPP performed as a part of interval CRS resulted in a very low incidence of platinum resistance. The post-operative morbidity was acceptable. These findings should be confirmed in a larger series and a randomized trial performed to demonstrate demonstrate its benefit over conventional surgery.Keywords
All Related Versions
- Published version: European Journal of Surgical Oncology, 47 (8), 2150.
This publication has 32 references indexed in Scilit:
- Neoadjuvant chemotherapy-related platinum resistance in ovarian cancerDrug Discovery Today, 2020
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian CancerNew England Journal of Medicine, 2018
- Hyperthermic Intraperitoneal Chemotherapy in Ovarian CancerNew England Journal of Medicine, 2018
- The role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: A ReviewIndian Journal of Surgical Oncology, 2016
- Is perioperative visual estimation of intra-abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy?Gynecologic Oncology, 2013
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian CancerNew England Journal of Medicine, 2011
- A Phase 3 Trial of Bevacizumab in Ovarian CancerNew England Journal of Medicine, 2011
- Is the Easier Way Ever the Better Way?Journal of Clinical Oncology, 2011
- “Stemness” Genomics Law Governs Clinical Behavior of Human Cancer: Implications for Decision Making in Disease ManagementJournal of Clinical Oncology, 2008
- The Effect of Debulking Surgery after Induction Chemotherapy on the Prognosis in Advanced Epithelial Ovarian CancerNew England Journal of Medicine, 1995